Effect of thrombopoietic stimulation on platelet life span in healthy human volunteers
| . | Day 1 . | Day 8 . | Day 12 . | Day 18 . |
|---|---|---|---|---|
| Platelet concentration (×103/μL) | ||||
| Treated | 230 ± 43 | 354 ± 51 | 522 ± 90 | 420 ± 75 |
| Pvs day 1 | .0001 | .0001 | .0001 | |
| Placebo | 210 ± 47 | 228 ± 23 | 241 ± 28 | 230 ± 17 |
| MPV (fL) | ||||
| Treated | 8.0 ± 0.6 | 8.1 ± 0.6 | 7.7 ± 0.8 | 7.7 ± 0.6 |
| Pvs day 1 | .2 | .17 | ||
| Placebo | 8.1 ± 0.7 | 7.9 ± 0.3 | 8.0 ± 0.7 | 7.9 ± 0.4 |
| Platelet life span (hs) | ||||
| Treated | 205 ± 18 | 226 ± 22 | 212 ± 23 | 178 ± 53 |
| Pvs day 1 | .03 | .45 | .48 | |
| Pvs day 8 | .05 | |||
| Placebo | 193 ± 12 | 212 ± 9 | 200 ± 10 | 214 ± 30 |
| Platelet mass turnover (×105fL/μL/d) | ||||
| Treated | 3.6 ± 1.1 | 4.6 ± 0.8 | 6.3 ± 2.1 | 7.5 ± 2.1 |
| Pvs day 1 | .0008 | .0009 | ||
| Placebo | 3.95 ± 0.9 | 3.5 ± 0.1 | 4.4 ± 0.1 | 3.4 ± 0 |
| Mpl ligand level (pg/mL) | ||||
| Treated | 119 ± 63 | 150 ± 93 | 102 ± 59 | 98 ± 66 |
| Placebo | 74 ± 20 | 71 ± 23 | 76 ± 12 | 75 ± 13 |
| . | Day 1 . | Day 8 . | Day 12 . | Day 18 . |
|---|---|---|---|---|
| Platelet concentration (×103/μL) | ||||
| Treated | 230 ± 43 | 354 ± 51 | 522 ± 90 | 420 ± 75 |
| Pvs day 1 | .0001 | .0001 | .0001 | |
| Placebo | 210 ± 47 | 228 ± 23 | 241 ± 28 | 230 ± 17 |
| MPV (fL) | ||||
| Treated | 8.0 ± 0.6 | 8.1 ± 0.6 | 7.7 ± 0.8 | 7.7 ± 0.6 |
| Pvs day 1 | .2 | .17 | ||
| Placebo | 8.1 ± 0.7 | 7.9 ± 0.3 | 8.0 ± 0.7 | 7.9 ± 0.4 |
| Platelet life span (hs) | ||||
| Treated | 205 ± 18 | 226 ± 22 | 212 ± 23 | 178 ± 53 |
| Pvs day 1 | .03 | .45 | .48 | |
| Pvs day 8 | .05 | |||
| Placebo | 193 ± 12 | 212 ± 9 | 200 ± 10 | 214 ± 30 |
| Platelet mass turnover (×105fL/μL/d) | ||||
| Treated | 3.6 ± 1.1 | 4.6 ± 0.8 | 6.3 ± 2.1 | 7.5 ± 2.1 |
| Pvs day 1 | .0008 | .0009 | ||
| Placebo | 3.95 ± 0.9 | 3.5 ± 0.1 | 4.4 ± 0.1 | 3.4 ± 0 |
| Mpl ligand level (pg/mL) | ||||
| Treated | 119 ± 63 | 150 ± 93 | 102 ± 59 | 98 ± 66 |
| Placebo | 74 ± 20 | 71 ± 23 | 76 ± 12 | 75 ± 13 |